PubMed Trending Research Digest — July 25, 2026

Automated digest · 96 articles · 15 research areas · July 25, 2026

Overview

Across this week’s set of studies, a dominant theme is mechanism-led precision: multiple papers connect specific molecular circuits (metabolic, immune, epitranscriptomic, or signaling) to clinically actionable outcomes. In oncology, examples include metabolic drivers of metastasis and therapy resistance (e.g., ADSL–fumarate in TNBC; 5-FU metabolite–GPCR/β-arrestin signaling driving resistance), as well as mutation-linked remodeling of the ubiquitin–proteasome system and evolution-informed frameworks for anticipating adaptive resistance. In neurodegeneration, work on complement activation early in synucleinopathy and refined microglial state maps emphasizes that immune pathways and “state space” phenotyping may offer earlier therapeutic windows than traditional binary activation models.

A second major thread is improved diagnostics and stratification using scalable biomarkers. Plasma phospho-tau panels help distinguish early-onset Alzheimer’s from frontotemporal dementia, while large proteomics and blood-based neurofilament light chain endpoint feasibility address practical issues of assay heterogeneity for trial design. In infection, host-protein/peptide signatures (AAT and derived peptides) are explored to differentiate bacterial vs viral pneumonia, and host-directed anti-inflammatory strategies (ATRA for SFTSV) highlight the value of targeting systemic inflammation rather than only the pathogen. Several studies also stress that better measurement—whether molecular (single-cell/spatial omics, proteomics) or clinical (patient-reported outcomes, subgroup tailoring)—is key to translating evidence into more reliable decision-making.

Finally, the digest shows a strong translational push in therapeutics and care pathways: new or expanding targeted treatments (CAR-T for CLDN18.2 gastric cancer; CSF-1R inhibition in TGCT; TYK2 inhibition in PsA; long-acting RSV prevention with clesrovimab) sit alongside perioperative and supportive interventions (immunonutrition around cystectomy, procedure-specific pain guidance for hip arthroplasty, and hemoperfusion/acid-base meta-analyses in critical care). Together, these studies reflect a broader shift toward combining targeted biology with pragmatic implementation—using biomarkers, mechanistic targets, and optimized protocols to improve outcomes across diverse diseases.

---

Cancer metabolism and pro-metastatic signaling

Global, regional, and national burden of road injuries 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

This Global Burden of Disease Study 2023 analysis estimated global, regional, and national incidence, mortality, and morbidity of road injuries by road injury type and nature-of-injury for 204 countries and territories from 1990 to 2023. It quantified long-term trends and geographic disparities in road injury burden to identify intervention gaps relevant to the UN Decade of Action for Road Safety targets. These estimates provide an evidence base for prioritizing road-safety policies and resource allocation to reduce deaths and serious injuries.

The Lancet. Public health · (2026) · View on PubMed ↗ · Free PDF ↗

α-fluoro-β-alanine functions as a β-arrestin1-biased ligand of S1PR2 to upregulate DPD expression in cancer cells.

This work identified α-fluoro-β-alanine (FBAL), a catabolite of the chemotherapeutic 5-fluorouracil (5-FU), as a β-arrestin1-biased ligand of sphingosine-1-phosphate receptor 2 (S1PR2) in colorectal cancer cells. The key finding was that FBAL–S1PR2 signaling upregulated dihydropyrimidine dehydrogenase (DPD) via GRK6-dependent phosphorylation of S1PR2, driving 5-FU resistance. Clinically, this links a 5-FU metabolite to a specific GPCR–β-arrestin pathway that could be targeted to overcome resistance.

Tan M, Shao H, Zhang X et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondrial SLC25A46 Rewires Fatty Acid Oxidation to Promote Cell Proliferation and Ferroptosis Evasion in Ovarian Cancer by Stabilizing CACT.

This study investigated the role of the mitochondrial intermembrane bridging protein SLC25A46 in ovarian cancer, using human ovarian cancer samples and mechanistic experiments to define how SLC25A46 affects metabolism and ferroptosis. The key finding was that SLC25A46 is upregulated in ovarian cancer and promotes cell proliferation and ferroptosis evasion by stabilizing CACT (carnitine-acylcarnitine translocase) and rewiring fatty acid oxidation to increase ATP and NADPH production, including via protection from MARCHF5-related effects. Scientifically and therapeutically, this identifies the SLC25A46–CACT axis as a potential target to suppress ovarian cancer growth and restore ferroptosis sensitivity.

Gao Y, Hao J, Zhang X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Inhibition of the Metalloproteinase ADAMTS5 Suppresses Colorectal Cancer Metastasis via the PEDF/Wnt/β-Catenin Pathway.

This study investigated the role of the metalloproteinase ADAMTS5 in colorectal cancer (CRC) metastasis and the underlying mechanism involving PEDF/Wnt/β-catenin signaling. It found that ADAMTS5 is upregulated in CRC tissues and that inhibiting ADAMTS5 suppresses CRC metastasis through modulation of the PEDF/Wnt/β-catenin pathway. These findings are clinically significant because ADAMTS5 could be a therapeutic target to block metastatic progression in CRC via a defined signaling axis.

Sun X, Zhang H, Hu Y et al. · Cancer medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression.

This study investigated whether pharmacological inhibition of UFMylation—targeting the UFMylation E3 ligase complex core protein DDRGK1—can reprogram tumor and immune microenvironments to treat glioblastoma, using two DDRGK1 inhibitors (Osimertinib via covalent mechanism and CP-24). It found that both compounds disrupt the DDRGK1–UFL1 interaction, globally suppress UFMylation, inhibit ER-phagy, and induce ER stress responses that drive long-term glioblastoma regression. The results identify DDRGK1/UFMylation as a druggable vulnerability and provide a mechanistic rationale for combining ER-stress/ER-phagy modulation with immunologically favorable tumor microenvironment remodeling.

Tan P, Liu Z, Hu X et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Exosomes in cancer drug resistance: dual roles in therapy failure and emerging precision therapeutics.

This review discussed how cancer-derived exosomes contribute to drug resistance while also serving as emerging tools for precision therapeutics, integrating mechanisms and translational implications. The key finding is that exosomal cargo (e.g., P-gp, PD-L1, miR-21, lncRNA H19) can remodel the tumor microenvironment and activate pathways such as PI3K/AKT and MAPK, thereby promoting therapy failure and immune evasion. Scientifically and clinically, it proposes the “exosome paradox” framework to guide strategies that both block resistance-promoting exosomes and harness exosomes for targeted treatment delivery.

Tegegne BA, Belew H, Teffera ZH et al. · Cancer cell international · (2026) · View on PubMed ↗ · Free PDF ↗

ADSL drives fumarate mediated scrib-rictor complex formation to promote metastasis dissemination in triple-negative breast cancer.

This study investigated how the metabolic enzyme ADSL and its fumarate output regulate SIRP-rictor complex formation to drive metastasis dissemination in triple-negative breast cancer (TNBC) using tumor/normal metabolomics, chemoproteomic succination profiling, and in vivo metastasis models. The authors found that ADSL-driven fumarate promotes SIRP-rictor complex formation, thereby enhancing metastatic dissemination. These findings link a specific metabolic reprogramming axis (ADSL–fumarate) to pro-metastatic signaling and suggest a potential metabolic target for limiting TNBC spread.

Fan Y, He X, Deng W et al. · Molecular cancer · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cell therapy and targeted immunotherapies (CAR-T, TCE, ADC, checkpoint modulation)

First CAR T-Cell Therapy Approved for Solid Tumors.

China studied satricabtagene autoleucel (satri-cel), a claudin 18.2–targeting CAR T-cell therapy, in patients with claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer. In a phase II trial, the CAR T cells increased progression-free survival and overall survival. This first solid-tumor CAR T approval highlights a clinically actionable target (CLDN18.2) but underscores the need for further work to improve CAR T efficacy in solid tumors.

Cancer discovery · (2026) · View on PubMed ↗

NOD1/2 signaling in macrophages drives adaptive immune resistance in cancer.

The authors investigated whether nucleotide-binding oligomerization domain-containing proteins NOD1 and NOD2 in macrophages control adaptive immune resistance to cancer therapies. In murine tumor models, genetic ablation of NOD1/2 (or RIPK2) and pharmacologic inhibition impaired resistance across multiple antitumor modalities, including immune checkpoint blockade, adoptive T-cell therapy, and cytotoxic chemotherapy. This identifies the macrophage NOD1/2–RIPK2 pathway as a potential therapeutic target to overcome treatment resistance in diverse cancers.

Wei X, Yang L, Wang Y et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

A phase 1/2 clinical study (IMC-C103C-101; NCT03973333) evaluated IMC-C103C, a T cell receptor bispecific ImmTAC targeting MAGE-A4×CD3, in HLA-A*02:01+ patients with advanced solid tumors expressing the cancer-testis antigen MAGE-A4. The trial used weekly intravenous dosing with step-up dosing and dose escalation guided by the mTPI-2 method to assess safety, preliminary anti-tumor activity, pharmacokinetics/pharmacodynamics, and biomarkers. This work tests a targeted HLA-restricted T-cell engager strategy for MAGE-A4-expressing malignancies and informs next-step development based on early clinical activity and tolerability.

Sweis RF, Melero I, Davar D et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease.

This review studied next-generation immunotherapies beyond immune checkpoint blockade, focusing on T cell engagers (TCEs) and antibody-drug conjugates (ADCs) across cancer and immune-mediated inflammatory disorders (IMIDs). It found that TCEs can redirect cytotoxic T cells to kill targets independently of MHC restriction, while ADCs deliver cytotoxic payloads via receptor-mediated internalization, potentially addressing resistance and toxicity limitations of checkpoint inhibitors. The synthesis provides mechanistic and translational context for designing and selecting TCE/ADC strategies, including discussion of the CD47/SIRPα innate immune checkpoint as a case study.

Abdelaziz AM, Shokr MM · Biochemical pharmacology · (2026) · View on PubMed ↗

A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death.

This mechanistic cancer study created lysine acetyltransferase (KAT)-based chemically induced proximity (CIP) molecules, termed KAT-TCIPs, to induce oncogene-induced cell death in diffuse large B cell lymphoma (DLBCL). The lead KAT-TCIP redirected p300/CBP to activate cell-death networks repressed by the oncogenic driver BCL6 and reprogrammed the epigenome to initiate apoptosis. This provides a targeted small-molecule approach to selectively trigger death in BCL6-driven lymphoma cells and potentially reduce relapse risk.

Nix MN, Gourisankar S, Bowman KJ et al. · Cell · (2026) · View on PubMed ↗

Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.

This preclinical study tested a tri-specific NK cell engager designed to therapeutically target CD47 to inhibit multiple myeloma by overcoming CD47-mediated immune evasion. The key finding was that blocking CD47 signaling with the tri-specific engager enhanced anti-myeloma immune activity (including macrophage phagocytosis and NK cell function) and inhibited tumor progression in the experimental setting. This is significant because it provides a rationale for CD47-targeted NK engager strategies to address resistance and improve outcomes in multiple myeloma patients who do not respond to standard therapies.

Sumankan R, Sungwan P, Boonsatit N et al. · Cancer immunology, immunotherapy : CII · (2026) · View on PubMed ↗ · Free PDF ↗

Targeted mRNA Delivery Using Bispecific Antibody-Lipid Nanoparticle Complexes.

This study developed and tested targeted mRNA delivery using bispecific antibody–lipid nanoparticle complexes (TbsAb-LNPs) that bind both the LNP polyethylene glycol (PEG) component and a cellular target to enhance extrahepatic uptake. The key finding was that the bispecific targeting platform enabled targeted LNP uptake in vitro as a prerequisite for tissue- and cell-specific delivery beyond the liver. Scientifically, it advances a modular strategy for improving the specificity of mRNA therapeutics where conventional LNPs have limited extrahepatic targeting.

Hickey JC, Roach T, Cassaidy B et al. · Molecular pharmaceutics · (2026) · View on PubMed ↗

γδ T cells show distinct responses to CMV after stem cell transplantation.

This study examined how γδ T cells respond to cytomegalovirus (CMV) after allogeneic hematopoietic stem cell transplantation (aHSCT) by combining longitudinal single-cell RNA sequencing with paired T cell receptor (TCR) sequencing across five post-transplant time points. It found patient-specific expansion of non-Vγ9Vδ2 γδ T cell clones, particularly within Vδ1+ and Vδ3+ subsets, associated with differences in CMV reactivation status. The significance is that clonal, subset-resolved γδ T cell dynamics may help predict or understand immune reconstitution outcomes after aHSCT in CMV contexts.

Sibbertsen F, Song Z, Ly C et al. · Journal of molecular medicine (Berlin, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Clinical oncology trials and treatment optimization

Incidence, risk factors and tumor spectrum of second primary cancers after gastric cancer: a multicenter cohort study with long-term follow-up.

This multicenter cohort study evaluated long-term incidence, risk factors, and tumor spectrum of second primary cancers (SPCs) in gastric cancer survivors who underwent curative-intent radical gastrectomy (2007–2021) in the MAGIS cohort. The key findings (truncated in the abstract provided) focus on quantifying SPC risk over follow-up and identifying clinical factors associated with SPC occurrence, along with detection patterns and stage distribution. Clinically, the results aim to inform long-term surveillance strategies after gastrectomy to detect SPCs earlier and potentially improve outcomes.

Gao X, Han W, Lu L et al. · BMC medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond.

This review article evaluated precision medicine strategies in advanced/metastatic pancreatic cancer, focusing on targeting mutant KRAS and emerging “KRAS and beyond” molecular approaches. The key finding was that the advent of KRAS inhibitors—highlighted by clinically meaningful activity reported from the RASolute 302 trial—expands the theoretical eligibility for targeted therapeutics beyond previously small biomarker-defined subgroups. This is significant because it frames how KRAS-directed therapy could translate molecular advances into improved patient outcomes and guides future combination and resistance-focused development.

Schürmann H, Park W, O’Kane GM et al. · Targeted oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).

This phase II again study investigated abemaciclib rechallenge in hormone receptor-positive, HER2-negative metastatic breast cancer patients who progressed after prior abemaciclib plus endocrine therapy, using a strategy of switching endocrine therapy while continuing abemaciclib (switching AI/tamoxifen to fulvestrant or fulvestrant to AI). The key finding was that continuing abemaciclib with endocrine therapy after progression produced measurable progression-free survival (PFS) outcomes as the primary endpoint in this post–CDK4/6 inhibitor setting. The clinical significance is that it tests whether abemaciclib can be reused (“rechallenged”) to extend disease control for patients with limited options after initial CDK4/6 inhibitor exposure.

Nishimura M, Kogawa T, Sugiyama K et al. · Breast cancer research and treatment · (2026) · View on PubMed ↗ · Free PDF ↗

TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.

The TANGENT phase III randomized study evaluated emactuzumab, a CSF-1R inhibiting monoclonal antibody, in patients with tenosynovial giant cell tumors (TGCT) who were not adequately treatable with surgery. The trial design targets tumor biology by inhibiting CSF-1R signaling via a receptor dimerization interface mechanism to reduce tumor-associated macrophage activity. If efficacy and safety are confirmed, emactuzumab could provide a shorter, less burdensome systemic option for TGCT compared with long-term CSF-1R pathway inhibitor therapy.

Gelderblom H, Palmerini E, van de Sande M et al. · Future oncology (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer.

This review article summarized evidence on tailored strategies to overcome third-generation EGFR tyrosine kinase inhibitor (TKI) resistance in EGFR-mutated non-small cell lung cancer (NSCLC). It organizes resistance mechanisms into on-target alterations (e.g., EGFR C797S and other secondary kinase domain mutations), off-target pathway activation (e.g., MET or HER2 amplification, RAS-MAPK signaling, oncogenic fusions), and neuroendocrine transformation to small-cell lung cancer. Clinically, it frames how molecular profiling can guide combination or switch strategies to improve outcomes after third-generation TKI failure.

Saporita I, Farinea G, Lombardi E et al. · Expert opinion on therapeutic targets · (2026) · View on PubMed ↗

Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study.

This retrospective real-world comparative study evaluated telitacicept versus conventional immunotherapy in patients with acetylcholine receptor antibody–positive generalized myasthenia gravis (AChR-Ab+ gMG), using propensity score matching (1:1) in 215 total patients (ChiCTR2500109279). The key finding was that telitacicept showed differences in treatment response and safety outcomes relative to conventional immunotherapy in this broader AChR-Ab+ gMG population than typical RCT cohorts. Clinically, it supports telitacicept’s effectiveness and informs real-world risk–benefit considerations for AChR-Ab+ gMG patients.

Yang Y, Kang N, Zhu Y et al. · ImmunoTargets and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review.

This systematic review analyzed whether progression-free survival (PFS) outcomes for identical myeloma regimens varied across newly diagnosed myeloma trials, focusing on bortezomib/lenalidomide/dexamethasone (VRd) and lenalidomide/dexamethasone (Rd) arms without transplant. The key finding was that PFS outcomes for the same regimen differed across trials, and the review aimed to identify contributors such as informative censoring and diagnostic reclassification after 2014 (e.g., smoldering myeloma reclassified as myeloma). This is significant for oncology evidence synthesis because it cautions against naive cross-trial comparisons of “identical” regimens in multiple myeloma.

Mohyuddin GR, Vaquera-Alfaro HA, Godara A et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

This analysis studied how to redefine functional high-risk (FHR) multiple myeloma in the era of upfront quadruplet therapy plus autologous stem cell transplantation (QUAD + ASCT) using 310 newly diagnosed MM patients. The key finding was that the historical FHR definition (progression within 18 months with expected OS <2 years) may not optimally capture risk under modern QUAD + ASCT treatment, prompting identification of alternative cutoff(s) and associated outcome factors. Scientifically and clinically, redefining FHR can improve risk stratification and guide subsequent therapy selection after initial treatment.

Ravi G, Dhakal B, Callander NS et al. · Cancer · (2026) · View on PubMed ↗ · Free PDF ↗

RNA modifications in cancer: regulators of tumor evolution and therapeutic response.

This review examined how RNA modifications (including m6A, m1A, m5C, m7G, pseudouridine, and A-to-I editing) regulate tumor evolution and therapeutic response by acting through epitranscriptomic “writers,” “readers,” and “erasers.” The key finding is that dysregulated RNA modification networks can control transcript stability, translation, and other RNA metabolism processes that shape cancer progression and treatment sensitivity. Scientifically, it frames RNA modification machinery as a mechanistic bridge between epitranscriptomic mapping and actionable therapeutic strategies.

Gu X, He Y, Xu Z et al. · Molecular cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.

This review synthesized current knowledge on tumor evolution, focusing on signaling pathways, molecular mechanisms, and therapeutic targets, and how modern technologies can track evolutionary dynamics. The key finding is that high-throughput sequencing, single-cell and spatial omics, lineage tracing, computational modeling, and noninvasive biopsy approaches collectively enable reconstruction of tumor heterogeneity and evolutionary trajectories. This is significant because it supports evolution-informed therapeutic targeting strategies designed to anticipate and counter adaptive resistance.

Zhang KY, Zhu XZ, Yan YX et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

This phase 3 randomized superiority trial (EBMT-SAAWP RACE; NCT02009747) studied whether adding eltrombopag to standard immunosuppressive therapy (horse ATG plus cyclosporine A) improves outcomes as front-line treatment for severe aplastic anemia in treatment-naive patients. The key finding from the final 2-year analysis was that the eltrombopag arm had a significantly higher 2-year cumulative incidence of complete response than standard IST alone (62.4% vs a lower comparator, as reported). This provides evidence that eltrombopag can enhance durable hematologic response when combined with first-line immunosuppression in severe aplastic anemia.

Risitano AM, Iacobelli S, Kulasekararaj A et al. · American journal of hematology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Biomarkers for diagnosis, prognosis, and response

Circulating alpha-1 antitrypsin and its c-terminal peptides differentiate bacterial from viral community-acquired pneumonia.

Researchers studied whether circulating alpha-1 antitrypsin (AAT) and its C-terminal peptides can distinguish bacterial from viral community-acquired pneumonia in 81 prospectively enrolled adults at hospital admission (day 0) and day 3. Using ELISA for AAT and LC-based quantification of nine AAT-derived C-terminal peptides, the study found that AAT/peptide profiles can differentiate bacterial versus viral CAP. This could reduce inappropriate antimicrobial use by providing a host-protein/peptide diagnostic signal early in infection.

Pashai Fakhri M, Börner FR, Held J et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias.

Large-scale plasma proteomics was used to profile 1,318 samples from international cohorts to find blood-based protein biomarkers for differential diagnosis and molecular staging across Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). More than 200 proteins were dysregulated across dementia groups, with glial fibrillary acidic protein (GFAP) increasing along the AD continuum and integrin alpha-V and integrin alpha-M (ITGAV/ITGAM) consistently reduced. This provides clinically actionable, scalable molecular signatures that may improve dementia subtype discrimination and track disease progression.

Bellomo G, Vermunt L, In ‘t Veld S et al. · Nature aging · (2026) · View on PubMed ↗ · Free PDF ↗

Single-Cell Analysis of Residual Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy Reveals TFAM-Mediated Immunoregulation in Dendritic Cells.

This study performed single-cell analysis of tumor microenvironments in 14 patients with esophageal squamous cell carcinoma (ESCC) who received neoadjuvant immunochemotherapy (nICT) to relate cellular programs to treatment response. Using nonnegative matrix factorization (NMF), it identified immunosuppressive cellular programs associated with minimal or no pathological tumor regression and implicated TFAM-mediated immunoregulation in dendritic cells. These findings suggest TFAM-driven dendritic-cell immunoregulation as a mechanistic biomarker and potential target for improving nICT responsiveness in ESCC.

Chen L, Feng T, Zhou J et al. · Cancer research · (2026) · View on PubMed ↗

Use of blood-based neurofilament light chain as an endpoint in clinical trials of neurodegenerative conditions: a scoping review.

This scoping review examined interventional neurodegenerative clinical trials (2013–2024) and related post hoc analyses that used blood-based neurofilament light chain (serum or plasma NfL) as an endpoint. The key finding was that blood NfL is increasingly used and is feasible as a trial endpoint across multiple neurodegenerative conditions, but heterogeneity in assays, sampling, and analytical approaches limits direct comparability. This is significant for trial design because it informs how to standardize blood NfL measurement to improve regulatory and scientific utility of NfL as a neuroaxonal injury biomarker.

Zheng Y, Bhalala OG, Chin KS et al. · Journal of neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Multiomics integrative bioinformatics analysis of gene expression characteristics and molecular mechanisms in preeclampsia placental tissue.

This bioinformatics study integrated multiple preeclampsia placental transcriptome and single-cell RNA-seq datasets from GEO to identify gene expression characteristics and molecular mechanisms in preeclampsia. Using differential expression analysis, Weighted Gene Co-expression Network Analysis (WGCNA), and machine learning to derive molecular subtypes and key pathways, it aimed to clarify placental dysfunction drivers underlying preeclampsia. The results could support biomarker discovery and mechanistic stratification for improved prediction and targeting of preeclampsia.

Li N, Tian L, Wei H · Artificial cells, nanomedicine, and biotechnology · (2026) · View on PubMed ↗ · Free PDF ↗

Immune checkpoint profiling of B7-H proteins predicts survival and treatment response in metastatic clear cell renal cell carcinoma.

This retrospective cohort study profiled immune checkpoint B7-H family proteins (B7-H3, B7-H4, B7-H5, B7-H7) in primary tumors from 145 patients with metastatic clear cell renal cell carcinoma (ccRCC) and related expression to aggressiveness, treatment response, and survival. The key finding was that compartmentalized, heterogeneous expression patterns—assessed by immunohistochemistry—were associated with prognosis and treatment response, with B7-H3 detected in both tumor and stromal compartments. This suggests that B7-H immune checkpoint profiling could help predict outcomes and potentially guide immunotherapy selection in metastatic ccRCC.

Emaldi M, Rey-Iborra E, Mosteiro L et al. · The journal of pathology. Clinical research · (2026) · View on PubMed ↗ · Free PDF ↗

Anatomical and Histologic Response to Neoadjuvant Therapy: Recurrence Patterns Among Poor Responders. A Multi-institutional Observational Cohort Study.

This multi-institutional observational cohort study evaluated colorectal liver metastases (CRLM) patients undergoing curative-intent hepatectomy after neoadjuvant therapy, integrating anatomical response using the Tumor Burden Score ratio (TBSr) with histologic response using Tumor Regression Grade (TRG). It found that combining anatomical and histologic response measures improves characterization of recurrence patterns among poor responders. Clinically, this supports more accurate post-neoadjuvant risk stratification to guide surveillance and potential escalation of therapy in CRLM.

Baldo A, Akabane M, Elemosho A et al. · Annals of surgery · (2026) · View on PubMed ↗

Blood-based multimodal biomarker models for differentiating early-onset Alzheimer’s disease from frontotemporal dementia: a longitudinal study of early-onset dementia and family members (LEAF) study.

This longitudinal LEAF study evaluated blood-based multimodal biomarker models to differentiate early-onset Alzheimer’s disease (EOAD) from early-onset frontotemporal dementia (EOFTD) in patients aged ≤65 years, measuring plasma p-tau217, p-tau181, neurofilament light (NfL), and GFAP by immunoassay. The key finding was that plasma p-tau217 and p-tau181 showed high discriminative performance between EOAD and EOFTD (AUCs reported as 0.831 and 0.862, respectively). Clinically, these results support using plasma phospho-tau biomarkers to improve early-onset dementia diagnosis and guide appropriate patient stratification.

Kwon HS, Moon SY, Hwang M et al. · Journal of neurology · (2026) · View on PubMed ↗

---

Neurodegeneration, neuroinflammation, and CNS immune mechanisms

Microglial states revisited: from homeostasis to disease.

This review studied how microglial states transition from homeostasis to disease, integrating evidence from single-cell/single-nucleus transcriptomics, chromatin accessibility profiling, and spatial multi-omics across developmental and disease contexts. It found that microglia do not fit simple binary “resting vs activated” or “M1 vs M2” models, instead occupying a multidimensional transcriptional state space shaped by genotype, environment, and age. Scientifically, it reframes microglial phenotyping using sensome/homeostatic and disease-associated signatures to better interpret neuroinflammatory mechanisms.

Eggen BJL, Kooistra SM · Nature reviews. Neuroscience · (2026) · View on PubMed ↗

Complement dysregulation during the early phases of synucleinopathy.

This study examined complement dysregulation during early synucleinopathy by using a rat α-synuclein pre-formed fibril (PFF) model to probe immune mechanisms linking pathological α-syn to neurodegeneration. The key finding (from the provided context) is that complement activation can occur early in synucleinopathy, addressing whether complement is directly triggered by pathological α-syn rather than only after overt neurodegeneration. This is significant because it identifies complement as a potential early therapeutic target in Parkinson’s disease–related synucleinopathies.

Khan H, Gifford M, Kordbacheh A et al. · Acta neuropathologica · (2026) · View on PubMed ↗ · Free PDF ↗

Genome-wide association analyses of borderline personality disorder identify 11 loci and highlight shared risk with mental and somatic disorders.

A genome-wide association study meta-analysis of borderline personality disorder (BPD) was conducted in European-ancestry samples (12,339 cases/1,041,717 controls discovery; 685 cases/107,750 controls replication) to identify susceptibility loci and risk genes. The study identified 11 independent associated genomic loci and 9 risk genes, with SNP-heritability of 17.3% and polygenic scores explaining 4.6% of phenotypic variance on the liability scale. These findings refine the genetic architecture of BPD and highlight shared genetic risk with both mental and somatic disorders, supporting cross-disorder biology for future mechanistic work.

Streit F, Awasthi S, Hall ASM et al. · Nature genetics · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Unlocking Sulforaphane’s Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons.

This preclinical study compared sulforaphane (SF) with the approved Friedreich ataxia therapy omaveloxolone (Omav) and with dimethyl fumarate (DMF) in induced pluripotent stem cell (iPSC)-derived sensory neurons from patients carrying expanded GAA repeats in the FXN gene (including a line with 550 GAA1 repeats). The key finding was that SF further supports FXN upregulation and beneficial modulation of epigenetic, inflammatory, and oxidative stress pathways in these patient-derived neurons, extending prior observations. This is significant because it strengthens the case for sulforaphane as a potential therapeutic candidate for FRDA alongside or beyond existing treatments like omaveloxolone.

Yang W, Thompson B, Miellet S et al. · Antioxidants & redox signaling · (2026) · View on PubMed ↗

Small Extracellular Vesicles From Cardiomyocytes Activate Microglia Aggravating HFpEF.

This study investigated whether small extracellular vesicles (sEVs) released from cardiomyocytes activate hypothalamic microglia and worsen HFpEF using a mouse model combining a long-term high-fat diet with the nitric oxide synthase inhibitor L-NAME. sEV-driven microglial activation and hypothalamic inflammation were linked to sympathetic activation, and microglial depletion with PLX3397 suppressed the downstream sympatho-excitatory effects. These findings suggest a heart-to-brain extracellular vesicle pathway as a mechanistic target to mitigate neuroinflammation in HFpEF.

Men L, Wang Q, Ren B et al. · Circulation research · (2026) · View on PubMed ↗

Associations of viral infections and antiviral vaccinations with anti-NMDAR and other forms of autoimmune encephalitis.

This systematic literature review assessed reported associations between viral infections and antiviral vaccinations and the occurrence of autoimmune encephalitis (AIE), including anti-NMDAR and other AIE subtypes. The key finding was that specific viral infection and vaccination links have been described across AIE subtypes, but the review highlighted gaps in a subtype-by-subtype, frequency-calibrated understanding. Clinically, the work underscores the need for better immunovigilance and mechanistic studies to clarify which triggers meaningfully increase AIE risk.

Bamberg S, Schulte-Frankenfeld PM, Kreye J · Brain, behavior, & immunity - health · (2026) · View on PubMed ↗ · Free PDF ↗

Soluble high-molecular-weight amyloid-β species derived from amyloid-β-laden brains induce cerebral β-amyloidosis.

This study investigated whether soluble high-molecular-weight amyloid-β (Aβ) species (>150 kDa) isolated from amyloid-β-laden brains could act as aggregation seeds to initiate cerebral β-amyloidosis. Intrahippocampal injection of these soluble >150 kDa Aβ species from plaque-laden amyloid-β precursor protein transgenic mice or Alzheimer’s disease patient tissue dramatically accelerated β-amyloidosis in transgenic mouse brains compared with controls. The results suggest that specific Aβ “strain-like” molecular forms can drive in vivo seeding and may inform therapeutic strategies targeting early aggregation seeds in Alzheimer’s disease.

Kashiwagi-Hakozaki M, Uchigami H, Naka Y et al. · Brain communications · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondria-targeted MXene-based nanozymes promote mitophagy and inhibit mtDNA-triggered cGAS/STING inflammation in osteoarthritis.

This preclinical study developed a mitochondria-targeted MXene-based nanozyme (MS@PMXene-TK) incorporating a mitochondria-targeting peptide (MTP-131) and a ROS-responsive thioketal-linked PEG shell to treat osteoarthritis (OA). The key finding was that the nanozyme promoted mitophagy and inhibited mtDNA-triggered cGAS/STING inflammatory signaling, thereby addressing mitochondrial dysfunction and chronic inflammation in OA models. Scientifically, it provides a subcellularly targeted nanotherapeutic strategy that couples ROS responsiveness with mitochondrial pathway modulation to reduce OA inflammation.

Li T, Zheng A, Zhu C et al. · Bioactive materials · (2026) · View on PubMed ↗ · Free PDF ↗

Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System.

This study used mass spectrometry to characterize the distribution of “big tau” (tau isoforms containing exon 4a) across the human central and peripheral nervous system, including postmortem tissues from Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and controls. It found distinct anatomical patterns of big tau isoform composition in CNS versus PNS regions and assessed disease relevance by comparing AD/ALS samples with controls. The significance lies in refining tau biology by mapping big tau isoforms, which may improve understanding of peripheral tau involvement and disease-specific tau signatures.

Koppisetti RK, Barthélemy NR, Horie K et al. · Annals of neurology · (2026) · View on PubMed ↗

Lyophilized platelet derived extracellular vesicles promote hemostasis and attenuate intracranial hemorrhage following traumatic brain injury.

This study evaluated whether lyophilized platelet-derived extracellular vesicles (LPEVs) reduce intracranial hemorrhage (ICH) and preserve blood–brain barrier (BBB) integrity after traumatic brain injury (TBI) in a murine TBI model, with LPEVs characterized by flow cytometry, scanning electron microscopy, and Nanosight and tested on human brain endothelial monolayers. The key finding was that LPEVs promoted hemostasis and attenuated ICH while maintaining BBB integrity following TBI. Clinically, this supports LPEVs as a potentially translatable, locally acting biologic therapy to improve outcomes after TBI-associated bleeding.

Trivedi A, Miyazawa B, Fields AT et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Infectious disease therapeutics and host-directed antiviral strategies

Viral syncytia evolve to resist interferon.

Researchers studied how SARS-CoV-2–driven syncytia affect antiviral interferon responses by using SARS-CoV-2 and Spike (S) replacement vesicular stomatitis virus (VSV) systems in cultured cells, human lung cell cultures, and hACE2 transgenic mice. They found that S-mediated syncytia impair interferon antiviral effects and that Spike substitutions modulating syncytia formation in Delta and Omicron produce parallel interferon resistance. This suggests syncytia formation is an evolutionary strategy that can also reduce antibody-mediated neutralization, informing antiviral and vaccine design.

Li T, Kang I, Ye J et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Mapping in-cell protein contact sites reveals hijacking of paraspeckles during influenza A virus infection.

In human cells infected with influenza A virus (IAV), the authors mapped native protein-protein contact sites using in-cell cross-linking mass spectrometry combined with structural modeling and functional assays. They uncovered previously unrecognized virus-host interactions, including host factors in the membrane-bound endoplasmic reticulum–Golgi system that regulate maturation of distinct haemagglutinin (HA) glycoforms and progressive disassembly events in the nucleus. This mechanistic map of in-cell contact sites identifies actionable host pathways hijacked by IAV during infection.

Kotova I, Mühlberg L, Gilep K et al. · Nature microbiology · (2026) · View on PubMed ↗ · Free PDF ↗

All-trans retinoic acid suppresses systemic inflammation induced by severe fever with thrombocytopenia syndrome virus in mice.

All-trans retinoic acid (ATRA), a vitamin A metabolite, was tested in patients with severe fever with thrombocytopenia syndrome virus (SFTSV) infection and in an SFTSV mouse model to determine whether ATRA modulates systemic inflammation. Patients showed depleted serum vitamin A/ATRA levels that correlated with worse systemic inflammatory response syndrome severity and mortality risk, and intraperitoneal ATRA suppressed virus-induced hyperinflammation in mice via PPARγ, which downregulated macrophage AP-1 transcriptional activity. These results support ATRA as a potential host-directed anti-inflammatory strategy for SFTSV.

Yu X, Wu J, Yin X et al. · Nature microbiology · (2026) · View on PubMed ↗

Viral protease-initiated lytic cell death as a universal antiviral mRNA therapy.

This preclinical study developed viral protease-initiated lytic cell death (VID), a universal antiviral mRNA platform, by engineering gasdermin-D (GSDMD) with viral protease-specific cleavage motifs to create VID activators (VIDAs). In a hepatitis A virus (HAV) mouse model, lipid nanoparticle (LNP)-encapsulated VIDA mRNA abolished viral replication and shedding and mitigated liver injury by triggering selective lytic cell death in infected cells. The work suggests a broadly applicable mRNA antiviral strategy that leverages viral protease activity to induce targeted, immune-relevant cell killing.

Li L, Yan XL, Wang HY et al. · Cell · (2026) · View on PubMed ↗

Divergent Autophagy Pathways in Plasmodium: Mechanisms, Functions, and Therapeutic Potential.

This review studied autophagy mechanisms in the malaria parasite Plasmodium, focusing on the reduced but functional set of autophagy-related (ATG) proteins and the autophagy marker/effector ATG8. It found that Plasmodial ATG8 shows branched localization and associates with the relict plastid (apicoplast) membrane, indicating parasite-specific, compartmentalized autophagy pathways. These findings are significant because they identify ATG8-linked autophagy features as potential therapeutic targets for malaria by exploiting differences from yeast/mammalian autophagy.

Rajput S, Mehra P, Nandi R et al. · Molecular microbiology · (2026) · View on PubMed ↗

---

Respiratory medicine (asthma, COPD, ARDS, RSV, influenza, rhinosinusitis)

EndoBridge 2025: pearls and highlights.

EndoBridge 2025 was studied as a scientific meeting, summarizing lectures and case-based discussions across endocrinology and metabolism topics for clinicians and researchers attending in Antalya, Türkiye (Oct 23–26, 2025). The key finding is that the program provided up-to-date coverage of major areas including pituitary, thyroid, adrenal, bone metabolism, neuroendocrine tumors, diabetes, obesity, clinical nutrition, and lipid disorders. Scientifically and clinically, it serves as a curated snapshot of emerging evidence and expert consensus to guide practice and future research.

Yildiz BO, Armenti M, Brandi ML et al. · Hormones (Athens, Greece) · (2026) · View on PubMed ↗

Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.

The LUNA phase III programme was designed as four multicentre, randomized, double-blind, placebo-controlled studies to test tozorakimab, an anti-IL-33 monoclonal antibody that inhibits both IL-33red and IL-33ox, in symptomatic COPD patients with high exacerbation risk despite optimized inhaled therapy. The programme includes OBERON (NCT05166889) and TITANIA (NCT05158387) and additional ongoing phase III trials within the same framework. This design aims to establish whether IL-33 blockade improves efficacy and safety outcomes in a clinically high-risk COPD population.

Watz H, Sciurba FC, Bonini M et al. · BMJ open respiratory research · (2026) · View on PubMed ↗ · Free PDF ↗

Use of tezepelumab for chronic rhinosinusitis with nasal polyps by eosinophilic endotype: WAYPOINT post-hoc analysis.

This post-hoc analysis of the phase 3 WAYPOINT randomized trial evaluated tezepelumab 210 mg versus placebo every 4 weeks in Japanese adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) stratified by eosinophilic chronic rhinosinusitis defined by the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (ECRS). Tezepelumab improved CRSwNP outcomes and showed efficacy and safety across the eosinophilic endotype subgroups, including reductions in nasal polyp burden and related symptoms. These findings support tezepelumab as an option for severe CRSwNP patients with eosinophilic disease biology, informing endotype-targeted treatment in clinical practice.

Fujieda S, Otori N, Han JK et al. · Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial.

This randomized clinical trial evaluated clesrovimab (105 mg) versus palivizumab in infants at increased risk for severe respiratory syncytial virus (RSV) disease during RSV season 1, and also assessed safety of a higher 210 mg clesrovimab dose in RSV season 2 among children who remained at risk. The key finding was that clesrovimab had an acceptable safety and tolerability profile across the two RSV seasons in this high-risk infant population. Clinically, it supports clesrovimab as a long-acting monoclonal antibody option for preventing severe RSV disease beyond a single season in infants who remain vulnerable.

Zar HJ, Bont LJ, Manzoni P et al. · JAMA pediatrics · (2026) · View on PubMed ↗

Prone positioning in ARDS.

This narrative review summarized evidence on prone positioning in acute respiratory distress syndrome (ARDS), including early use in intubated patients with PaO2/FIO2 <150 mmHg and the awake prone position (APP) approach in non-intubated patients. The key finding was that prone positioning consistently improves oxygenation and has evolved from rescue therapy to an integral lung-protective ventilation strategy, with APP showing promising results that require confirmation outside COVID-19. Clinically, the review supports broader ICU adoption while emphasizing the need for more routine, non-COVID validation of APP protocols.

Ehrmann S, Li J, Liu L et al. · Intensive care medicine · (2026) · View on PubMed ↗ · Free PDF ↗

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

This study characterized the airway transcriptome in severe asthma stratified by type 2 (T2) cytokine biomarker activity, analyzing bronchial biopsies and brushes from the UK Refractory Asthma Stratification Programme cohort. It compared T2 biomarker-high, -intermediate, and -low groups (plus healthy controls) before and after treatment with high-dose inhaled corticosteroids (ICS) to identify dysregulated genes and pathways. The work is significant because it may reveal distinct molecular drivers of T2-low severe asthma that could enable more targeted therapies beyond corticosteroids.

Shen J, Chaudhuri R, Bicknell S et al. · Allergy · (2026) · View on PubMed ↗ · Free PDF ↗

Cigarette Smoke-Exposed Alveolar Epithelial Cell-Derived Exosomes Exacerbate Skeletal Muscle Dysfunction Through HDAC2 Signalling.

This experimental study investigated how exosomes derived from cigarette smoke–exposed alveolar epithelial cells affect skeletal muscle dysfunction in the context of COPD, with emphasis on histone deacetylase 2 (HDAC2) signaling. Using the exosome inhibitor GW4869, it found that exosome-mediated signaling exacerbates skeletal muscle injury and is linked to reduced/altered HDAC2 pathway activity. Scientifically and clinically, targeting exosome release or HDAC2 signaling may represent a mechanistic approach to prevent COPD-related sarcopenia/skeletal muscle dysfunction.

Li C, Ou M, Jiang G et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗ · Free PDF ↗

Hemoperfusion during extracorporeal membrane oxygenation: an updated systematic review and meta-analysis of 8,151 patients.

This systematic review and meta-analysis evaluated the efficacy and safety of hemoperfusion (HP) added to extracorporeal membrane oxygenation (ECMO) versus ECMO alone in adults, pooling 8,151 patients across studies. The key finding is the comparative effect of ECMO+HP on all-cause mortality (with subgroup analyses by RCT vs non-RCT, ECMO type—VA vs VV—and etiology—cardiogenic shock vs cardiac arrest). Scientifically and clinically, it clarifies whether hemoperfusion provides outcome and safety benefits in ECMO-treated adults, informing critical care practice and future trial design.

Xie T, Yang C, Tao H et al. · Critical care (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardiovascular disease (heart failure, cardioprotection, dyslipidemia, vascular risk)

Does Characterization of Phenotypic Heterogeneity Provide Mechanistic Insights or Influence the Response to Treatment? Experience in Positive and Neutral Trials in Patients With Heart Failure and a Preserved Ejection Fraction.

This article reviewed and analyzed whether characterizing phenotypic heterogeneity in heart failure with preserved ejection fraction (HFpEF) can provide mechanistic insights or identify treatment responders, drawing on experience from positive and neutral HFpEF trials. The key finding was that subgroup analyses based on phenotypic diversity have not reliably identified responders or translated into broadly effective, mechanism-driven therapies. Scientifically, it argues that HFpEF heterogeneity alone has been insufficient for precision treatment selection, motivating more rigorous causal and biomarker frameworks.

Packer M, Schiattarella GG, Petrie MC et al. · Circulation · (2026) · View on PubMed ↗ · Free PDF ↗

Loss of ATP-Dependent Citrate Lyase Drives Left Ventricular Dysfunction by Metabolic Remodeling.

This study investigated how loss of ATP-dependent citrate lyase (ACLY/Acly) affects cardiac metabolism and function by using human heart tissue from healthy donors and patients with nonischemic cardiomyopathy and applying CRISPR-based approaches to model ACLY loss. The key finding was that ATP-dependent citrate lyase loss drove left ventricular dysfunction through metabolic remodeling, consistent with impaired acetyl-CoA production and downstream lipid synthesis support. These results position ACLY as a metabolic regulator and potential therapeutic target in nonischemic heart failure.

Liu S, Gammon ST, Tan L et al. · Circulation · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy.

This study assessed the population health impact of the 2026 American Heart Association/American College of Cardiology/multisociety dyslipidemia guideline on primary prevention statin eligibility among nonpregnant adults aged 30–79 years without known ASCVD using NHANES 2017–2023 data. The key finding was the guideline’s revised ASCVD risk estimation and expanded/modified statin-eligible populations would substantially change the proportion of adults recommended for primary prevention statin therapy. These results are clinically significant because they quantify how guideline updates could affect real-world statin prescribing and downstream cardiovascular risk reduction at the population level.

Anderson TS, Wilson LM, Sussman JB · JAMA · (2026) · View on PubMed ↗

GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.

This target trial emulation study used Veterans Health Administration data to compare overdose risk among Veterans with type 2 diabetes and opioid use disorder who initiated semaglutide or tirzepatide versus initiation of other diabetes medications (e.g., insulin, metformin, sulfonylurea, SGLT2 inhibitors). The key finding was that GLP-1 receptor agonist initiation was associated with a lower all-cause overdose risk compared with the diabetes medication comparator group. The clinical significance is that it supports a potential harm-reduction role for GLP-1RAs in high-risk patients with OUD, informing future observational replication and trial prioritization.

Kennedy KP, Bremseth-Vining R, Lynch KG et al. · The Journal of clinical psychiatry · (2026) · View on PubMed ↗

Activity-based proteomics analysis revealed that DNJ directly targeted ATP5F1 to alleviate high glucose induced cardiomyocyte injury.

This study examined the cardioprotective mechanism of the natural alkaloid 1-deoxynojirimycin (DNJ) in high-glucose–injured cardiomyocytes by using activity-based protein profiling (ABPP) to identify direct DNJ targets and then validating the interaction with ATP5F1. The authors found that DNJ directly targeted ATP5F1 and that this targeting alleviated high glucose–induced cardiomyocyte injury. Scientifically, the work pinpoints a specific mitochondrial ATP synthase subunit (ATP5F1) as DNJ’s direct molecular target, informing mechanism-based therapeutic development for diabetic cardiomyopathy.

Li X, Chen Y, Yang H et al. · Cell communication and signaling : CCS · (2026) · View on PubMed ↗ · Free PDF ↗

---

Renal, urologic, and perioperative surgical care

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.

In the phase 3, international PACE-B trial, patient-reported outcomes were assessed over 5 years in men with localized prostate cancer randomized to stereotactic body radiotherapy (SBRT) versus conventionally fractionated radiotherapy (CRT). At 5 years, urinary incontinence outcomes were favorable and comparable between SBRT and CRT, with leak-free rates reported as 64% (164/…). These long-term PROM data support patient-centered decision-making when choosing SBRT versus CRT for localized prostate cancer.

Cooper S, Patel J, Moore C et al. · European urology · (2026) · View on PubMed ↗ · Free PDF ↗

COVID-19 and Global Perinatal Health: Lessons Learned on Maternal-Neonatal Outcomes, Infant Feeding Practices, and Healthcare Economics Across Income Settings.

This narrative review synthesized evidence on how the COVID-19 pandemic affected maternal-neonatal outcomes, infant feeding practices, and healthcare economics across high-income countries (HICs) and low- and middle-income countries (LMICs). It found that both direct SARS-CoV-2 infection effects and indirect healthcare-system disruptions were associated with worse perinatal outcomes and altered neonatal care and breastfeeding, with substantial financial burden on healthcare institutions. The review highlights the need for resilient perinatal care and breastfeeding-support policies during ongoing and future health-system shocks.

Gunasekaran V, Woo S, Shetty AK et al. · American journal of perinatology · (2026) · View on PubMed ↗

Effect of high-dose versus standard-dose influenza vaccines on hospitalisation outcomes and mortality in older adults: a systematic review and meta-analysis.

This systematic review and meta-analysis studied randomized controlled trials comparing high-dose inactivated influenza vaccine (HD-IIV; 60 μg haemagglutinin per strain) versus standard-dose inactivated influenza vaccine (SD-IIV) in adults aged 65 years or older. HD-IIV showed improved hospitalisation outcomes and reduced mortality compared with SD-IIV across included trials. The results support preferential use of HD-IIV in older adults to reduce severe influenza-related outcomes at the population level.

Zhao W, Lian R, Zhao Y et al. · The lancet. Healthy longevity · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial.

This multicenter, randomized, double-blind phase 3 trial (SWOG S1600) studied whether perioperative specialized immunonutrition reduces 30-day complications compared with standard oral nutrition support in adults undergoing radical cystectomy for bladder cancer. The key finding was that immune-enhancing nutrition improved postoperative outcomes by lowering early complication rates relative to standard nutrition support. Clinically, it supports using targeted immunonutrition as an adjunct to surgery to reduce morbidity after radical cystectomy.

Hamilton-Reeves JM, Unger JM, Holzbeierlein JM et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

PROSPECT guideline for total hip arthroplasty: updated systematic review and procedure-specific postoperative pain management recommendations.

This PROSPECT collaboration updated systematic review evaluated evidence from randomized trials and systematic reviews (2020–June 2024) to produce procedure-specific postoperative pain management recommendations for elective primary total hip arthroplasty. It focuses on integrating analgesic efficacy and safety with functional recovery, including new evidence on motor-sparing regional techniques since the 2021 PROSPECT guideline. The guideline is clinically important for standardizing perioperative analgesia to improve pain control and rehabilitation outcomes after total hip arthroplasty.

Carella M, Bugada D, Van de Velde M et al. · Anaesthesia · (2026) · View on PubMed ↗ · Free PDF ↗

Sustainable miniaturized smartphone-coupled TLC platform for innovative cleaning validation: application to tizanidine combinations under challenging concentration ratios.

This work developed a sustainable, miniaturized smartphone-coupled thin-layer chromatography (TLC) platform to validate cleaning carryover of tizanidine (TZN) in combination with aceclofenac (ACF), ibuprofen (IBF), and paracetamol (PRC) under challenging concentration ratios. The key finding is that the at-line portable TLC approach enables rapid determination of TZN in multi-drug mixtures to support cleaning validation and reduce cross-contamination risk. Scientifically and clinically, the platform offers a practical monitoring tool for narrow-therapeutic-index, high-abuse-potential drugs like tizanidine in routine pharmaceutical quality control.

Abd El-Aziz MO, Nadim AH, Monir HH et al. · Scientific reports · (2026) · View on PubMed ↗ · Free PDF ↗

Sodium bicarbonate therapy in severe metabolic acidemia: an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials.

This individual patient data meta-analysis combined the BICAR-ICU and BICAR-ICU2 randomized trials to assess intravenous sodium bicarbonate therapy in adults with severe metabolic acidemia (pH ≤ 7.20). The key finding is the pooled estimate of effects on 90-day mortality and renal replacement therapy (RRT) use, along with evaluation of heterogeneity across prespecified subgroups. Clinically, it aims to resolve uncertainty about bicarbonate benefit in severe acidemia and to identify patient groups most likely to benefit or be harmed.

Fosset M, Pensier J, Jabaudon M et al. · Critical care (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

---

Autoimmune and inflammatory disorders (beyond oncology)

The 2026 British Society for Rheumatology guideline for pain management in people with inflammatory arthritis.

A British Society for Rheumatology guideline was developed for pain management in people with inflammatory arthritis (IA) using evidence from trial data, electronic health record analyses, and patient survey findings. The guideline addresses the mismatch between real-world long-term opioid/gabapentinoid prescribing and limited trial evidence, and emphasizes underused non-pharmacological pain care with supportive evidence. This provides an evidence-based, UK-specific framework to improve pain outcomes and prescribing practices across the IA life course.

Scott IC, Smith TM, Babatunde O et al. · Rheumatology (Oxford, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Caffeine and Cardiovascular Disease: A Scientific Statement From the American Heart Association.

This American Heart Association scientific statement synthesized evidence on caffeine intake and its associations with cardiovascular risk factors and cardiovascular diseases in human populations. It concludes that caffeine’s cardiovascular effects are complex and heterogeneous, often differing between acute versus chronic exposure and showing an inverse J-shaped pattern for naturally occurring caffeinated beverages in many studies. Clinically, the statement supports nuanced dietary guidance rather than a single universal recommendation about caffeine for cardiovascular prevention.

Marcus GM, Hu FB, van Dam RM et al. · Circulation · (2026) · View on PubMed ↗

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

The POETYK PsA-2 phase 3 randomized, double-blind trial evaluated the oral selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib for efficacy and safety in patients with active psoriatic arthritis (PsA), including biologic-naïve patients and those previously treated with tumor necrosis factor inhibitors. Over 52 weeks, patients received deucravacitinib 6 mg daily versus placebo, with apremilast 30 mg twice daily as a safety reference arm, and the study assessed outcomes such as ACR20 improvement. If sustained, deucravacitinib could expand targeted oral options for PsA with a mechanism distinct from TNF inhibition and PDE4 blockade.

Mease PJ, Chandran V, Armstrong AW et al. · Arthritis & rheumatology (Hoboken, N.J.) · (2026) · View on PubMed ↗

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial.

This randomized trial studied ruxolitinib cream in adults (≥18 years) with moderate atopic dermatitis (IGA 3, EASI >7, itch NRS ≥4) who had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) in the prior 12 months (TRuE-AD4, NCT06238817). The 8-week results reported that ruxolitinib cream improved atopic dermatitis signs and symptoms compared with the control regimen in this post–TCS/TCI population. These findings support ruxolitinib cream as a targeted topical option for adults with moderate AD when standard topical therapies fail.

Carrascosa JM, Prajapati VH, Hong HC et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · (2026) · View on PubMed ↗ · Free PDF ↗

Evaluating the pharmacokinetics, efficacy and safety of low-dose cannabidiol.

This article reviewed pharmacokinetics, pharmacodynamics, and safety evidence for low-dose cannabidiol (CBD) at doses ≤2.5 mg/kg or ≤175 mg/day (including oral CBD studies ≤150 mg). It found that low-dose CBD produces peak concentration (Cmax) and exposure (AUC) levels 5- to 100-fold lower than typical Epidiolex (20 mg/kg) dosing and showed very little evidence of physical or neurological effects in healthy volunteers. Scientifically and clinically, the review helps contextualize why low-dose OTC CBD may have limited measurable effects and supports more evidence-based dosing expectations.

Warren WG, Osborn M, Yates A et al. · British journal of clinical pharmacology · (2026) · View on PubMed ↗

Efficacy of magnesium-calcium ionic oral rinse for primary burning mouth syndrome: a randomized, double-blind, placebo-controlled trial.

This randomized, double-blind, placebo-controlled trial studied the efficacy and safety of a magnesium–calcium ionic oral rinse in patients with primary burning mouth syndrome (BMS). The key finding was that the magnesium–calcium oral rinse improved outcomes compared with placebo (with efficacy and safety assessed in the trial). This suggests that locally modulating the oral ionic microenvironment may offer a safer, non-systemic treatment strategy for chronic neuropathic orofacial pain in primary BMS.

Carrió N, Garawani BE, Alahmad A et al. · BMC oral health · (2026) · View on PubMed ↗ · Free PDF ↗

---

Musculoskeletal and sarcopenia interventions

Electroacupuncture Treatment on Sarcopenia in Patients Undergoing Maintenance Haemodialysis: An Effective Therapy.

This randomized controlled clinical study evaluated electroacupuncture (EA) as a treatment for sarcopenia in patients undergoing maintenance hemodialysis (MHD), enrolling 36 participants randomized to EA versus control. It found that EA delivered as 24 sessions (30 minutes, three times per week) improved sarcopenia outcomes compared with continuing usual lifestyle/treatment. The clinical significance is that EA may offer an effective, nonpharmacologic adjunct to improve muscle health in MHD patients with sarcopenia.

Chen R, Qian Q, Wang B et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗ · Free PDF ↗

---

Metabolic health, obesity, and fatty liver

Effects of Lifestyle Modification on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis evaluated whether lifestyle modification reduces intrapancreatic fat deposition (IPFD) by synthesizing studies in which lifestyle interventions were measured against IPFD outcomes. The key finding was that lifestyle modification improves IPFD, supporting IPFD as a modifiable ectopic fat depot linked to pancreatic disease risk. Scientifically, this strengthens the evidence base for targeting lifestyle-driven metabolic changes to reduce pancreatic fat accumulation and potentially lower future endocrine/exocrine pancreatic morbidity.

Ahmad S, Sul HH, Danpanichkul P et al. · Current obesity reports · (2026) · View on PubMed ↗ · Free PDF ↗

Durability and Safety of Imeglimin as an Add-On to DPP-4 Inhibitors in Japanese Type 2 Diabetes: The 104-Week FAMILIAR Trial.

This multicenter randomized placebo-controlled trial (FAMILIAR) evaluated imeglimin 1000 mg twice daily as an add-on to existing DPP-4 inhibitors in Japanese adults with type 2 diabetes over 104 weeks, including a focus on glycemic durability and safety in elderly patients. The key finding was that imeglimin maintained glycemic control over the long term (HbA1c change through week 104) while demonstrating an acceptable safety profile during the 24-week double-blind phase plus 80-week open-label extension. Clinically, it supports imeglimin as a durable, well-tolerated intensification strategy for Japanese patients inadequately controlled on DPP-4 inhibitor monotherapy.

Shimoda M, Osonoi T, Iwamoto M et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗

Work-to-sleep ratio as a novel marker of NAFLD risk: evidence from U.S. and Korean national cohorts.

This cohort study assessed whether the work-to-sleep ratio (WSR) predicts nonalcoholic fatty liver disease risk (MASLD) using U.S. and Korean national cohorts. The key finding is that WSR—capturing the balance between occupational time and sleep recovery—associates with NAFLD/MASLD risk more directly than work hours or sleep duration alone. Clinically, WSR could serve as a practical behavioral risk marker to identify individuals at higher risk for metabolic liver disease.

Zhong Y, Kou Y, Lu Z et al. · Nutrition & metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

---

Epigenetics, aging, and functional capacity

Multidomain Lifestyle Intervention in Mild Cognitive Impairment: Subgroup Analysis of the SUPERBRAIN-MEET Randomized Trial.

This prespecified subgroup analysis of the 24-week SUPERBRAIN-MEET randomized controlled trial studied whether a multidomain lifestyle intervention (MLI) delivered via face-to-face sessions plus digital platforms benefited adults with mild cognitive impairment (MCI) differently by sociodemographic factors, digital readiness, baseline cognitive status, and vascular risk profiles. The key finding was that the cognitive effects of the MLI varied across these prespecified subgroups rather than being uniform across all participants. These results support tailoring multidomain lifestyle programs for MCI by identifying which patient characteristics and baseline risks predict the strongest cognitive benefit.

Kim DA, Lee SM, Sun K et al. · Neurology · (2026) · View on PubMed ↗

Accelerated Epigenetic and Inflammatory Aging and Intrinsic Capacity.

This population-based cohort study examined cross-sectional and longitudinal associations between accelerated epigenetic and inflammatory aging and intrinsic capacity (IC), including domain-specific IC and sex differences, in older adults. The key finding was that accelerated epigenetic and inflammatory aging was associated with lower IC and that these aging measures related to IC decline over time. These results support using molecular aging signatures to identify individuals at risk for reduced functional capacity and to guide preventive interventions.

Rouch L, De Souto Barreto P, Rolland Y et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

Medical Students’ Attitudes, Perceptions, and Self-Reported Familiarity With Artificial Intelligence in Healthcare: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis synthesized studies reporting medical students’ attitudes, perceptions, and self-reported familiarity with artificial intelligence (AI) in healthcare. It emphasizes that prior research used heterogeneous survey instruments and that the review assessed construct harmonization, participant independence, heterogeneity, prediction intervals, risk of bias, and certainty of evidence. The findings are significant for designing AI literacy and curriculum interventions that match students’ measured needs and variability across settings.

Zhang W, Han J, Han X et al. · JMIR medical education · (2026) · View on PubMed ↗ · Free PDF ↗

Frailty mediates the association between sleep duration and physical, psychological, and cognitive multimorbidity in Chinese middle-aged and older adults.

This study analyzed data from the China Health and Retirement Longitudinal Study (CHARLS) to test whether frailty mediates the association between sleep duration and physical, psychological, and cognitive multimorbidity (PPC-MM) in Chinese middle-aged and older adults. Using multivariate logistic regression and Cox proportional hazards models (with nonlinear dose-response assessed by restricted cubic spline analysis), it found that frailty partially explains how sleep duration relates to PPC-MM risk. The significance is that addressing frailty could be a practical intervention target to reduce multimorbidity risk linked to sleep patterns.

Ding H, Li L, Luo G et al. · Scientific reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Genomics, gene regulation, and RNA/protein regulation

Mechanism of actin thin filament pointed-end elongation by leiomodin.

This study investigated the mechanism of actin thin filament pointed-end elongation in striated muscle, focusing on leiomodin (Lmod) regulation of actin dynamics alongside known capping proteins (CapZ and tropomodulin, Tmod) and the molecular ruler nebulin. The key finding is that leiomodin acts as an additional regulator promoting pointed-end actin filament elongation to maintain thin filament length uniformity. This advances the molecular understanding of sarcomere assembly and stability, with implications for muscle function and related myopathies.

Brotzman SB, Palmer NJ, Boczkowska M et al. · Nature communications · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Mitochondrial-derived vesicles drive budding-type fission of damaged lysosomes.

Researchers studied lysosomal renewal under hypoxia-reoxygenation stress and identified a budding-type fission (B-fission) pathway that restores lysosomal function. They found that damaged lysosomes generate membrane buds that undergo scission to form small, functional lysosomes independently of autophagic lysosome reformation, with mitochondrial-derived vesicles (MDVs) delivering the fission adaptor MFF to lysosomes to recruit DRP1. This mechanistic insight links mitochondrial signaling to lysosome integrity, offering new targets for diseases involving lysosomal dysfunction.

Luo Y, Yu J, Li Z et al. · Nature cell biology · (2026) · 1 citations · View on PubMed ↗

Promoter strength and position govern promoter competition through transcript-dependent insulation.

This study investigated how promoter strength and genomic position govern promoter competition using engineered promoter insertions into defined sites within the Sox2 locus. It found that the reduction in endogenous Sox2 transcription correlates with inserted promoter strength, that competition requires transcription from the inserted promoter, and that longer transcripts increase competition via transcript-dependent insulation. Scientifically, it clarifies the rules of long-range promoter competition and provides a framework for predicting gene regulation outcomes in development and disease.

Koska M, Nagano M, Swigut T et al. · Nature genetics · (2026) · View on PubMed ↗

Structures of dynamic interactors at native proteasomes by PhIX-MS and cryo-electron microscopy.

This structural proteomics study developed PhIX-MS (photo-induced in situ crosslinking-mass spectrometry) combined with cryo-electron microscopy to capture dynamic, transient interactors at native proteasomes. Using this workflow, the authors mapped the redox sensor TXNL1 at the proteasome regulatory particle (RP), including its dynamic thioredoxin-like domain near RPN2/PSMD1 and RPN13/ADRM1, and resolved RP structures bound to TXNL1. The findings clarify how redox sensing is physically coupled to proteasome function, informing models of substrate reduction prior to proteolysis.

Lee K, Negi H, Chen X et al. · Molecular cell · (2026) · View on PubMed ↗

RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity.

This study investigated how the RNA exonuclease REXO4 regulates R-loop homeostasis and anti-tumor immunity in human cells and mouse models. REXO4 resolved m6A-marked R-loops by 3’-5’ exonucleolytic cleavage of the RNA strand in RNA-DNA hybrids, with m6A promoting REXO4 localization to facilitate R-loop removal. REXO4 loss increased DNA damage, triggered interferon responses, and enhanced tumor immune infiltration, indicating that REXO4 suppresses anti-tumor immunity and may be a therapeutic target.

Zhang J, Bao K, Hou Y et al. · Molecular cell · (2026) · View on PubMed ↗ · Free PDF ↗

The orchestration of ciliary opus: Interplay of signalling molecules, GTPases, and trafficking machinery.

This Current Opinion review studied how primary cilia signaling is orchestrated by the interplay of intraflagellar transport (IFT) machinery, the BBSome coat complex, small GTPases, and trafficking regulators. It concluded that kinesin-2 and dynein-2 motors coordinate bidirectional receptor/signaling trafficking, while ciliary lipid composition and secondary messengers such as cAMP and Ca2+ regulate ciliary composition and signaling output. The synthesis frames ciliary “opus” as an integrated trafficking–signaling system relevant to tissue homeostasis and ciliopathy mechanisms.

Piyush R, Giri P, Shinde SR · Current opinion in cell biology · (2026) · View on PubMed ↗

Ligand regulation and function of preformed EGFR dimers.

This study used cryo-electron microscopy to determine the structural basis of ligand regulation and function of preformed epidermal growth factor receptor (EGFR) dimers. The key finding was a detailed structural view showing how preformed EGFR dimers are organized and regulated, refining the classic ligand-induced dimerization model for EGFR activation. This mechanistic structural insight can inform more precise therapeutic strategies targeting EGFR dimer states in cancer.

Zuo Y, Schwartz HT, Walker K et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

A genome-wide functional analysis of conserved intronic regions reveals essential roles for speckle-associated retained introns.

This genome-wide functional study used a dual CRISPR-Cas editing strategy to delete 2,600 conserved human intronic regions associated with intron retention, focusing on speckle-associated retained introns in human cells. The key finding was that a subset of these conserved “fitness” intronic sequences affected cell growth by altering intron retention and host gene expression, with deletions in nuclear speckle-associated retained introns in FNBP4 and DDX5 producing downstream effects. Scientifically, it establishes conserved retained introns as functional regulatory elements essential for normal cellular fitness and gene regulation.

Farhangmehr S, Braunschweig U, Wu M et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

Pan-cancer proteogenomic interrogation of the ubiquitin-proteasome system.

This study used harmonized pan-cancer proteogenomic data from up to 11 CPTAC cohorts to examine how somatic cancer-driver alterations remodel the ubiquitin-proteasome system (UPS) at the protein level, with emphasis on E3 ligases and TP53. It found that mRNA levels poorly predict UPS protein abundance, that a recurrent set of E3 ligases is dysregulated across cancers, and that somatic mutations—most notably TP53 loss—generate coherent UPS protein quantitative trait locus (pQTL) signatures. These findings support UPS protein remodeling as a mutation-linked mechanism of tumor evolution and suggest UPS components as potential prognostic biomarkers and therapeutic targets.

González-Robles TJ, Khan M, Sastourné P et al. · Cell death and differentiation · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

---

Microbiome and gut-derived metabolites

Endothelial cell-intrinsic NOD2 signaling regulates the intestinal immune response through the generation of effector and memory T cells.

The study examined how endothelial cell-intrinsic NOD2 signaling regulates intestinal immunity by driving effector and memory T cell generation, focusing on the NOD2–muramyl dipeptide axis relevant to Crohn’s disease genetics. NOD2 engagement by muramyl dipeptide promoted T cell homeostasis through endothelial programs that coordinate innate-adaptive immune cross-talk in the gut. This resolves a key NOD2 paradox in Crohn’s disease by linking a genetic risk pathway to how intestinal T cell responses are maintained.

Tsankov BK, Denney M, Ahn JSY et al. · Nature immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Gut Metabolism Links Precision Nutrition, Exercise, and Healthspan in Drosophila melanogaster.

This Drosophila melanogaster study tested whether a chemically defined diet (CDD) combining methionine restriction (MR), taurine supplementation (Tau), and moderate exercise improves healthspan and longevity, using targeted metabolomics with stable isotope tracing. The multimodal intervention additively extended lifespan while preserving reproductive capacity and improving locomotor function, alongside increased mitochondrial TCA cycle flux and improved gut redox homeostasis. Scientifically, it links gut metabolic remodeling to coordinated performance and lifespan extension, informing precision nutrition strategies that avoid trade-offs.

Wei F, Liu S, Sun Y et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Peptide LKLKLL is a more effective component of Akkermansia muciniphila which regulate glucolipid metabolism through GLP-1/GIP dual modulation.

This preclinical study examined whether the Akkermansia muciniphila–derived hexapeptide LKLKLL can modulate glucolipid metabolism via GLP-1/GIP dual regulation in cell and mouse models. It found that LKLKLL reduced body weight in high-fat diet–induced obese mice, improved glucose tolerance in diabetic models, and enhanced GLP-1 secretion (with GLP-1/GIP dual modulation). These results are significant because they support a defined microbial peptide as a translational candidate for obesity and diabetes therapies beyond live A. muciniphila.

Li Y, Ye D, Fu C et al. · Gut microbes · (2026) · View on PubMed ↗ · Free PDF ↗

Gut microbiota-driven metabolites modulate the development of stress-related mental disorders.

This review synthesized evidence that gut microbiota-driven metabolites modulate the development of stress-related mental disorders (e.g., depression, anxiety, PTSD) by altering systemic physiology. The key finding is that microbiome changes can shift metabolite production and circulation, which in turn influences host stress biology through multiple pathways (as summarized across preclinical and clinical studies). Clinically, it supports metabolite-centered mechanisms as potential targets for future diagnostics and therapeutics for stress-related psychiatric conditions.

Yuan M, Qin F, Wu L et al. · Translational psychiatry · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on July 25, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.